Profile data is unavailable for this security.
About the company
VBI Vaccines Inc. is a commercial-stage biopharmaceutical company. Through its approach to virus-like particles (VLPs), including an enveloped VLP (eVLP) platform technology and a proprietary mRNA-launched eVLP (MLE) platform technology, the Company develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system. The Company is focused on targeting and overcoming significant infectious diseases, including hepatitis B (HBV), coronaviruses, and cytomegalovirus (CMV), as well as aggressive cancers including glioblastoma (GBM). Its product pipeline includes an approved vaccine and multiple late- and early-stage investigational programs. PreHevbrio is its approved vaccine for hepatitis B. Its Prophylactic Candidates for coronavirus disease include VBI-2901, VBI-2905, VBI-2902, and others. VBI-1501 is its Prophylactic Candidate for cytomegalovirus. VBI-2601 and VBI-1901 are the therapeutic candidates for HBV and GBM.
- Revenue in USD (TTM)9.41m
- Net income in USD-83.99m
- Incorporated2016
- Employees131.00
- LocationVBI Vaccines Inc160 Second Street, CambridgeCAMBRIDGE 02142United StatesUSA
- Phone+1 (617) 830-3031
- Fax+972 8948-0660
- Websitehttps://www.vbivaccines.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Aditxt Inc | 329.75k | -43.31m | 296.05k | 47.00 | -- | 0.0092 | -- | 0.8978 | -3,088.09 | -3,088.09 | 12.12 | 131.74 | 0.0185 | 0.6082 | 0.8393 | 7,015.96 | -242.33 | -192.78 | -1,548.63 | -321.59 | -46.09 | -- | -13,105.77 | -7,208.65 | 0.0458 | -3.53 | 0.5084 | -- | -30.90 | -- | -18.11 | -- | -- | -- |
NovAccess Global Inc | 0.00 | -1.74m | 308.26k | 1.00 | -- | -- | -- | -- | -0.1193 | -0.1193 | 0.00 | -0.2246 | 0.00 | -- | -- | 0.00 | -1,836.30 | -2,185.89 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -177.93 | -- | -- | -- |
Meso Numismatics Inc | 2.87m | -10.15m | 326.01k | 1.00 | -- | -- | -- | 0.1135 | -0.8144 | -0.8144 | 0.2303 | -2.07 | 0.5424 | -- | 76.15 | -- | -191.67 | -192.08 | -- | -- | 68.95 | 60.24 | -353.35 | -821.49 | 0.0257 | -0.0755 | -- | -- | 57.49 | 116.97 | -76.03 | -- | 149.35 | -- |
Neximmune Inc | 0.00 | -20.62m | 341.69k | 6.00 | -- | 0.4907 | -- | -- | -18.59 | -18.59 | 0.00 | 0.66 | 0.00 | -- | -- | 0.00 | -140.56 | -115.07 | -224.94 | -165.07 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 48.25 | -- | -44.65 | -- |
Endonovo Therapeutics Inc | 255.72k | -4.40m | 357.15k | 0.00 | -- | -- | -- | 1.40 | -0.0652 | -0.0652 | 0.0003 | -0.072 | 0.2256 | -- | -- | -- | -388.54 | -303.26 | -- | -- | 96.21 | 74.38 | -1,722.26 | -5,956.27 | -- | -1.38 | -- | -- | 85.15 | -- | -495.02 | -- | -- | -- |
Cannabis Global, Inc. | 2.62m | -3.16m | 431.88k | 3.00 | -- | 0.0172 | -- | 0.1649 | -0.0324 | -0.0324 | 0.008 | 0.0058 | 0.1929 | 14.13 | 5.92 | -- | -27.77 | -164.57 | -140.92 | -- | -2.45 | -- | -143.95 | -831.07 | 0.1799 | -1.75 | 0.3238 | -- | 5,829.78 | -- | -58.94 | -- | -- | -- |
VBI Vaccines Inc | 9.41m | -83.99m | 456.05k | 131.00 | -- | -- | -- | 0.0485 | -6.93 | -6.93 | 0.4818 | -0.2166 | 0.0923 | 1.40 | 37.05 | 71,839.70 | -81.40 | -46.58 | -171.57 | -58.62 | -24.06 | -277.46 | -881.79 | -2,755.98 | 0.2116 | -1.60 | 1.13 | -- | 702.40 | 20.94 | 17.18 | -- | -32.07 | -- |
GlobeStar Therapeutics Corp | 0.00 | -1.98m | 465.17k | -- | -- | -- | -- | -- | -0.0023 | -0.0023 | 0.00 | -0.0015 | 0.00 | -- | -- | -- | -38,103.72 | -4,657.88 | -- | -- | -- | -7,790.20 | -- | -2,834,410.00 | -- | -21.00 | -- | -- | -- | -- | -31.01 | -- | -- | -- |
Capstone Therapeutics Corp | 0.00 | -358.00k | 512.23k | 2.00 | -- | -- | -- | -- | -6.58 | -38.12 | 0.00 | -60.70 | 0.00 | -- | -- | -- | -113.46 | 141.94 | -199.60 | 173.06 | -- | -- | -- | -- | -- | -2.92 | -- | -- | -- | -- | 52.46 | -- | -- | -- |
International Stem Cell Corp | 8.32m | -529.00k | 560.31k | 29.00 | -- | -- | -- | 0.0673 | -0.0661 | -0.0661 | 1.04 | 0.0355 | 1.46 | 2.54 | 11.31 | 286,965.50 | -12.02 | -29.22 | -84.86 | -73.82 | 58.62 | 59.49 | -8.22 | -21.01 | 0.4785 | -3.94 | 0.9254 | -- | -4.78 | -6.82 | 60.42 | -- | -34.45 | -- |
Yield10 Bioscience Inc | 750.00k | -12.70m | 595.81k | 29.00 | -- | -- | -- | 0.7944 | -135.92 | -135.92 | 1.95 | -9.71 | 0.1697 | -- | -- | 25,862.07 | -287.44 | -91.26 | -- | -108.09 | -- | -- | -1,693.60 | -2,279.74 | -- | -- | -- | -- | -86.67 | -35.94 | -6.55 | -- | 1.84 | -- |
Holder | Shares | % Held |
---|---|---|
Perceptive Advisors LLCas of 16 Apr 2024 | 1.26m | 4.40% |
Alyeska Investment Group LPas of 31 Mar 2024 | 626.44k | 2.18% |
The Vanguard Group, Inc.as of 30 Jun 2024 | 184.44k | 0.64% |
Geode Capital Management LLCas of 30 Jun 2024 | 172.70k | 0.60% |
Cambridge Investment Research Advisors, Inc.as of 30 Jun 2024 | 67.11k | 0.23% |
Morgan Stanley & Co. LLCas of 31 Mar 2024 | 31.81k | 0.11% |
Alpine Global Management LLCas of 31 Mar 2024 | 25.00k | 0.09% |
Simplex Trading LLCas of 30 Jun 2024 | 19.35k | 0.07% |
CapFinancial Partners LLCas of 31 Mar 2024 | 12.34k | 0.04% |
Steward Partners Investment Advisory LLCas of 30 Jun 2024 | 8.09k | 0.03% |